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Abstract
Background: IgG4-related disease, described around the years 2000 as a form of autoimmune pancreatitis, is now
increasingly accepted as a systemic syndrome. The diagnosis is based on both comprehensive and organ-specific
criteria. For the kidney, Mayo clinic classification and the guidelines of the Japanese Nephrology Society are used.
Ultimately, together with parameters that characterize every organ or apparatus involved, the key element is the
confirmation of growing levels of IgG4 in blood or in tissues.
Case presentation: We describe a male patient with chronic renal failure associated to hypertension without
proteinuria. IgG4-related disease was diagnosed through renal biopsy. After an initial positive response to steroids,
he presented tinnitus, and histological assessment showed cerebral and subsequently cardiac damage, both IgG4-
related. This case appears unique for the type of histologically documented cardiac and neurological parenchymal
involvement, and at the same time, exemplifies the subtle and pernicious course of the disease. Frequently, blurred
and non-specific signs prevail. Here, kidney damage was associated with minimal urinary findings, slowly
progressive renal dysfunction and other factors that can be equivocated in the differential diagnosis. Neurological
involvement was represented by tinnitus alone, while cardiac alterations were completely asymptomatic.
Conclusions: This report is representative of the neurological and cardiac changes described in the literature for
IgG4-related disease, which may be correlated or not with the renal form and highlights the need, in some cases,
of targeted therapeutic approaches. In addition to glucocorticoids, as in this case, rituximab may be necessary.
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Background
IgG4-Related Disease (IgG4-RD) is a systemic immune-
mediated fibroinflammatory condition. Several well-known
illnesses (Mikulicz’s disease, Riedel’s thyroiditis, Morbus
Ormond, Kuttner’s tumor), once considered unrelated, are
now unified under this systemic disorder [1]. The epidemi-
ology is not well defined: it usually affects adults from
middle-age onwards, predominantly male.
The pathogenesis of IgG4-RD can be highly variable.
The presentation of an unknown antigen by B-cells and
plasmablasts to CD4+ T-lymphocytes triggers the local
production of fibrogenic cytokines, namely IL-1β, IFN-γ
and TGF- β, which contribute to spread the fibrosis to
different organs. For unknown reasons, the previous
interaction, involving CD4+ Tfh2 (IL-4 and IL-10),
induces a switch to IgG4 production within lymph node
germinal centers. Different autoantigens, like proteins
expressed in bile duct epithelia and in pancreatic acinar
cells, have been proposed as targets/triggers in IgG4-RD
patients, although they are not found in all the organs
potentially involved [2].
Both B and T-cells are central in IgG4-RD pathogen-
esis, as demonstrated by the efficacy of B-cell depletion
therapy [3, 4].
The most common affection is lymphoplasmacytic
sclerosing pancreatitis, but many others can be listed
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: gaetano.lamanna@unibo.it
1Unit of Nephrology, Dialysis and Transplantation, Department of
Experimental Diagnostic and Specialty Medicine, University of Bologna, S.
Orsola Malpighi Hospital, Via G. Massarenti 9 (Pad. 15), 40138 Bologna, Italy
Full list of author information is available at the end of the article
Comai et al. BMC Nephrology          (2019) 20:418 
https://doi.org/10.1186/s12882-019-1587-4
relating to this disease: dacryoadenitis and Mikulicz
disease, lymph node adenopathies, aortitis, arteritis,
sclerosing cholangitis, tubulointerstitial nephritis, mem-
branous nephropathy and retroperitoneal fibrosis [1].
Both central and peripheral nervous system are impli-
cated in IgG4-RD, with a large number of different signs
and symptoms, depending on the nervous structure
injured [5, 6].
Unfortunately, the heterogeneity and the vagueness of
these symptoms do not permit a clear and standardized
identification, causing many delays and difficulties in the
diagnosis.
The current approach to the diagnosis of IgG4-RD is
based on a combination of comprehensive and organ-
specific diagnostic criteria. Concerning the kidney, the
Mayo clinic classification and the guidelines of the
Japanese Nephrology Society are applied [7–9].
We describe here a particular case report, somehow
unique, characterized by both neurological and cardio-
logical involvement, with slightly different features from
the currently available literature [6].
Case presentation
A 51-year-old man with a history of hypertension,
nephrolithiasis and benign prostatic hyperplasia was
admitted to our hospital because of progressive chronic
kidney disease with worsening proteinuria and low
serum complement levels. The patient’s anamnesis was
negative for nephrotoxic drugs and included asthmatic
bronchitis, treated with desensitization immunotherapy,
inguinal and submandibular lymphadenopathy, with a
histological pattern described as reactive follicular hyper-
plasia, and a recent suspected connective tissue disease.
At the time of admission, the patient’s general condi-
tions were good. Laboratory tests revealed the following:
elevated serum creatinine levels (183 μmol/L), high
serum total IgG and IgG4 levels (2882 mg/dL and 1853
mg/dL, respectively), high serum IgE levels (4442 UI/
mL) without eosinophilia, low serum complement levels
(72.8 mg/dL), elevated free kappa and lambda chains
with normal ratio, negative serum and urine immuno-
fixation test, and a proteinuria of 340 mg/24 h without
hematuria. Blood pressure was under control and the
general physical examination was unremarkable.
Abdominal ultrasound displayed both enlarged kidneys
(12.5 cm longitudinal diameter for the right kidney, 14
cm for the left) showing hyperechogenic cortex with soft
margin and incisures resulting from past lesions, without
any other abdominal abnormalities. Enhanced computed
tomography (CT) highlighted multiple renal low-density
lesions (Fig. 1).
Owing to the patient’s history of lymphadenopathy,
PET/CT was performed. It showed tenuously subman-
dibular, retroperitoneal and left inguinal hypermetabolic
adenopathy, without a clear evidence of infectious focus.
The kidney biopsy revealed chronic nephritis with se-
vere tubulointerstitial fibrosis, with no storiform pattern,
and parenchymal atrophy along with lymphoplasma cells
Fig. 1 Bilateral renal low density lesions on enhanced computed tomography (CT)
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infiltrate (Fig. 2a, b); immunohistochemistry showed that
15–20% of IgG were IgG4 type. The Congo red test was
negative. An inguinal lymph node biopsy highlighted
follicular hyperplasia with plasmacytosis, with IgG4/IgG
ratio > 50% (Fig. 2c, d).
We used the Japanese diagnostic criteria for IgG4-
related disease published by Kawano et al. [8]. The pa-
tient was diagnosed with IgG4-RD in a definite way in
view of the following:
– presence of some kidney damage: decreased kidney
function, elevated serum IgG level, low serum
complement levels, elevated serum IgE level
(criterion 1);
– abnormal renal radiologic findings: multiple low-
density lesions on enhanced CT (Fig. 1; criterion 2),
– elevated serum IgG4 level greater than 135 mg/dl
(criterion 3);
– histologic findings in the kidney: dense
lymphoplasmacytic infiltration with 14–16 infiltrating
IgG4-positive plasma cells counted in different high
power fields (HPF) at 400x magnification; two HPF
are shown in Fig. 3a and b (criterion 4a);
– histologic findings in extra renal organs: follicular
hyperplasia with plasmacytosis and IgG4/IgG ratio >
50% in lymph nodes (criterion 5), despite IgG4/IgG
ratio of 15–20% in kidney specimen.
The patient was treated with methylprednisolone 0.6
mg/kg/day for 3 days, later tapering until oral methyl-
prednisolone 16 mg daily. Since we saw a gradual im-
provement in laboratory data during the follow-up
period, we prescribed oral methylprednisolone 4 mg
daily for 6 months as maintenance steroid therapy.
Plasma creatinine was 150.1 μmol/L, C3 level normalized
and there was no albuminuria. We also noticed a net re-
duction of IgG4 from 1853 to 178.8 mg/dL.
One year later, in spite of stable laboratory parameters
and steroid maintenance therapy (4mg/day), a new onset
of tremors appeared associated to increased sialadenitis-
related symptoms, left exophthalmos and left tinnitus. A
cerebral MRI was performed which highlighted a patho-
logical lesion with homogeneous enhancement on post-
contrast studies, involving the left infratemporal fossa, the
foramen rotundum and the inferior orbital fissure (Fig. 4).
The patient was then submitted to a transsphenoidal
endocranial biopsy of the pathological lesion that
showed an intense fibrotic inflammation within the
normal structure of a nerve with a plasma cell-rich in-
filtrate, mainly IgG4, as documented by immunohisto-
chemistry (Fig. 5a, b, c).
Because of ECG alteration (right branch block and
abnormal repolarization with pericarditis or possible is-
chemic signs) without cardiological symptoms, we per-
formed an echocardiography. The patients showed
Fig. 2 Diffuse tubulointerstitial fibrosis with two normal glomeruli (a); lymphoplasmatic infiltrate with parenchymal atrophy (b); a lymphoid follicle
with a reactive germinal centre surrounded by mature plasma cells (yellow arrows) (c); fibrotic infiltration, Giemsa 40XIgG, IgG4-positive plasma
cells (yellow arrows) (d)
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normal left ventricular functions (EF 75%) with left and
right ventricular wall thickness at the upper limits; no
pericardial effusion could be detected. An endomyocardial
biopsy, made to rule out any myocardial involvement,
revealed the presence of unspecific subendocardial fibrosis
without plasma cells (CD138 staining negative, not
shown), as well as the presence of perivascular IgG4 posi-
tive plasma cells infiltrating cardiac tissue (Fig. 5d, e, f).
We then prescribed a second-line therapy with steroid
enhancement first, followed, after 1 month, by four Rituxi-
mab (RTX) weekly infusions (375mg/m2 each one). The
timeline of the case described here is detailed in Fig. 6.
After 1-year follow-up, the clinical conditions were
stable; plasma creatinine was 152 μmol/L with a reduction
of IgG and IgG4 (958mg/dL and 93.3mg/dL respectively).
Discussion
The neurological manifestations of IgG4-RD could be
related either to the direct injury of the central or per-
ipheral nervous system or to the mass effect [6]. Various
authors describe four different forms of neurological
complications. IgG4-related orbital disease, in which
IgG4-RD can implicate all extra-ocular muscles, levator
palpebrae, structures emerging from the optic canal, or
superior and inferior orbital fissure; according to the
affected structure, different symptoms are described.
Goto et al. reported a case of IgG4-related ophthalmic
disease misdiagnosed as intraocular tumor [10]. IgG4-
RD could also occur as hypophysitis. The documentation
of IgG4-RD-induced lesions of the pituitary gland intro-
duces IgG4-related hypophysitis as a novel pathological
entity, although plasmacytic/IgG4 involvement is already
known in several other diseases, including both the more
common lymphocytic-autoimmune and granulomatous
pituitary disease and other rarer forms [11].
Moreover, IgG4-RD peripheral nerve disease has been
also described, with symptoms caused both by the mass
effect and by the contribution of the epineurium.
Ohyama et al. reported the first case of IgG4-related
neuropathy where the patient exhibited sensory and
motor disturbances in the extremities; the authors
showed the histopathological findings of a sural nerve
Fig. 3 Dense lymphoplasmacytic infiltration with 14–16 infiltrating IgG4-positive plasma cells. a and b show two different high power fields at
400x magnification
Fig. 4 Pathological lesion biopsied (indicated by arrows) on Assial MRI 3DT1 fat saturated post-contrast sequence
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biopsy, characterized by a clear thickening with abun-
dant collagen fibers and infiltration of IgG4-positive
plasma cells in the epineurium [12].
Finally, there are also cases of IgG4-RD meningeal dis-
ease. Among the most common causes of non-malignant
meningeal inflammation, the disease can manifest in the
substance of the dura mater, like pachymeninges of the
brain or the spinal cord; rarely, IgG4-RD can affect the
substance of pia mater (leptomeninges) without
pachymeningeal involvement. In this condition, there is
usually a mild lymphocytic pleocytosis in the cerebro-
spinal fluid. Parenchymal brain damages were found in a
few patients, always associated with pachymeningitis [13].
The case described here appears to be peculiar, because
it presents cerebral involvement without pachymeningitis,
together with cardiac and renal parenchyma infiltrations.
There are three reports of IgG4-RD cases complicated
by constrictive pericarditis [14–16]: in all of them, the
Fig. 5 Intense fibrotic inflammation with a lot of plasma cells (a), involving a normal structure [a nerve on the left] (b) and IgG4+ plasma-cells
staining (c). Diffuse and mild subendocardic and myocardic fibrosis (d), fibrosis with unspecific cellular alterations (e), perivascular IgG4+ plasma-
cells deposition [< 30%] (f)
Fig. 6 Timeline of the reported case. The laboratory values out of the normal ranges are highlighted in bold. sCreat, serum creatinine;
ECG: Electrocardiography
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diagnosis was histological through both autopsy and
pericardiectomy. Mori et al. published a case of IgG4-
RD in which autoimmune pancreatitis was associated
with pericardial thickening diagnosed by contrast-
enhanced CT scan of the chest [17]. In another case re-
port, the pericardial involvement was identified through
IgG4-positive plasma cells in pericardial effusion [18];
only a few studies have illustrated cytological examin-
ation in patients with IgG4-RD [19]. Vascular lesions,
especially aortitis and periaortitis, represent further well-
represented cardiological manifestations of IgG4-RD
[20]. The affection of coronary arteries has also been de-
scribed: Patel et al. have recorded a case of a 53-year-old
Hispanic man who was sent to the emergency center
and diagnosed with sudden cardiac death secondary to
systemic IgG4-RD, with injury of coronary arteries [21].
IgG4-RD presents features appearing heterogeneously
associated and it is not known how exactly the different
organs are implicated [1, 6, 10, 11, 20–22].
IgG4 is the least abundant IgG subclass (< 5% of the total
IgG); approximately 50% of IgG4 molecules consist of
heavy chains that are weakly linked by non-covalent forces.
Following the dissociation of these bonds, the chains re-
combine randomly creating asymmetric bispecific anti-
bodies with two different antigen-binding sites [23]. Both B
and T-cells are central in IgG4-RD pathogenesis, as demon-
strated by the efficacy of B-cell depletion therapy [3, 4].
Firstly, activated IgG4+ B-cells and plasmablasts could
enhance IgG4-RD both directly, with the production of
IgG4-autoantibodies, and indirectly, through the activa-
tion of pathogenetic CD4 + T-cells. During the different
stages of IgG4-RD, somatic hypermutation of IgG4+
plasmablasts suggest the continuative role of CD4+ T-
cells in the pathogenesis of IgG4-RD [6]. At the begin-
ning, dendritic cells or B-cells present antigens to T-
lymphocytes in lymph nodes; at the same time, local
signs from the innate immune system might determine
the T helper cell polarization and their differentiation
into effector or memory T-cells. Activated B-cells mi-
grate to germinal centers and undergo somatic hyper-
mutation, differentiating into memory B-cells or
plasmablasts. The underlying mechanisms might be that,
among CD4+ T-cells, both Th2 and regulatory T-cells,
sustained by putative autoreactive B-cells, may drive col-
lagen deposition and induce IgG4 class-switch and plas-
mablast expansion [23]. It is important to underline that,
because of the absence of CD20 receptor on plasma-
blasts, RTX interferes with the principle B-cell/T-cell
cross-talk process, which could explain the effectiveness
of the therapy with RTX.
Conclusions
This case report shows how the diagnosis of IgG4-RD is
often challenging. In this particular instance, the patient
presented a slow deterioration of renal function in
concomitance with a series of other factors potentially
causing chronic renal damage: high blood pressure, im-
munological and alloreactive profile.
Respiratory symptoms, such as hypertrophy of sub-
mandibular and paratracheal lymph nodes, allergic rhin-
itis and/or conjunctivitis, must be considered as an
alarm bell. Unfortunately, the proteinuria is not a char-
acterizing factor, and the renal signs appeared very
faded. The neurological involvement might present itself
in many different ways, and it can sometimes be distin-
guished by one significant parenchymal infiltration, like
in this case, causing annoying and unremarkable symp-
toms, as tremor and tinnitus. The heart involvement
shows atypical aspects and it can be asymptomatic in the
initial phases. The early diagnosis, although difficult, is
fundamental for a positive outcome.
Even if the patient initially responded to steroid ther-
apy, he underwent disease relapse when doses were
tapered, and our experience agrees with previous find-
ings indicating that steroids often are not enough to
control the disease [24].
RTX seems to be the most effective second-line treat-
ment, although randomized controlled trials are still
lacking.
Abbreviations
EF: Ejection fraction; IFN-γ: Interferon gamma; IgG4-RD: IgG4-Related Disease;
IL-10: Interleukin 10; IL-1β: Interleukin 1 beta; IL-4: Interleukin 4;
RTX: Rituximab; TGF-β: Transforming growth factor beta
Acknowledgements
The authors thank Dr. Deborah Malvi of the Unit of Oncology and Transplant
Pathology of our hospital for her precious contribution in microscopy
experiments.
Authors’ contributions
GC: main investigator, review of clinical charts, management of a database to
collect the essential clinical and demographic data of the patient,
preparation of the manuscript; VC: support in the collection of clinical and
demographic data of the patient, and in the preparation of the manuscript;
BF, OL: histological assessments; ES: support in the preparation of the
manuscript, in particular concerning the hematological aspects; FT: collection
of clinical and demographic data of the patient, draft and revision of the
manuscript; AA: collection, analysis and interpretation of clinical and
demographic data of the patient, proofreading; MC: support in the
preparation of the manuscript, final revision, proofreading, submission; RL:
support in the preparation of the manuscript, in particular concerning the
neurological aspects; GLM: conception of the work, main supervisor in all the
stages of the work, final substantial revision of the manuscript. All authors
have read and approved the manuscript.
Funding
There was no support/funding for this manuscript.
Availability of data and materials
The datasets generated and/or analysed during the current study are not
publicly available due [for data privacy and security reasons, the EHRs can be
viewed upon authorized access through credentials by patients and
providers], but are available from the corresponding author on reasonable
request.
Comai et al. BMC Nephrology          (2019) 20:418 Page 6 of 7
Ethics approval and consent to participate
Not applicable.
Consent for publication
Written informed consent was obtained from the patient to publish this case
report and any accompanying images.
Competing interests
The authors declare that they have no competing interests.
Author details
1Unit of Nephrology, Dialysis and Transplantation, Department of
Experimental Diagnostic and Specialty Medicine, University of Bologna, S.
Orsola Malpighi Hospital, Via G. Massarenti 9 (Pad. 15), 40138 Bologna, Italy.
2Unit of Oncology and Transplant Pathology, Department of Experimental
Diagnostic and Specialty Medicine, University of Bologna, S. Orsola Malpighi
Hospital, Via G. Massarenti 9 (Pad. 18), 40138 Bologna, Italy. 3Unit of
Hemolymphopathology, Department of Hematology & Oncology, University
of Bologna, S. Orsola Malpighi Hospital, Via G. Massarenti 9 (Pad. 8), 40138
Bologna, Italy. 4IRCCS Institute of Neurological Sciences of Bologna and
Department of Biomedical and Neuromotor Sciences, University of Bologna,
Via Altura 3, 40139 Bologna, Italy.
Received: 27 March 2019 Accepted: 13 October 2019
References
1. Quattrocchio G, Roccatello D. IgG4-related nephropathy. J Nephrol. 2016;
29(4):487–93.
2. Kamekura R, Takahashi H, Ichimiya S. New insights into IgG4-related disease:
emerging new CD4+ T-cell subsets. Curr Opin Rheumatol. 2019;31(1):9–15.
3. Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA,
Deshpande V, Smyrk TC, Chari S, Stone JH. Rituximab for IgG4-related
disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74(6):1171–7.
4. Quattrocchio G, Barreca A, Demarchi A, et al. IgG4-related kidney disease:
the effects of a rituximab-based immunosuppressive therapy. Oncotarget.
2018;9(30):21337–47.
5. AbdelRazek MA, Venna N, Stone JH. IgG4-related disease of the central and
peripheral nervous systems. Lancet Neurol. 2018;17(2):183–92.
6. Raissian Y, Nasr SH, Larsen CP, et al. Diagnosis of IgG4-related
tubulointerstitial nephritis. J Am Soc Nephrol. 2011;22(7):1343–52.
7. Kawano M, Saeki T, Nakashima H, et al. Proposal for diagnostic criteria for
IgG4-related kidney disease. Clin Exp Nephrol. 2011;15(5):615–26.
8. Umehara H, Okazaki K, Nakamura T, et al. Current approach to the diagnosis
of IgG4-related disease - combination of comprehensive diagnostic and
organ-specific criteria. Mod Rheumatol. 2017;27(3):381–91.
9. Goto H, Ueda S. Immunoglobulin G4-related ophthalmic disease involving
the sclera misdiagnosed as intraocular tumor: report of one case.
OculOncolPathol. 2016;2(4):285–8.
10. Anno T, Kawasaki F, Takai M, et al. Clinical course of pituitary function and
image in IgG4-related hypophysitis. Endocrinol Diabetes Metab Case Rep.
2017;2017. https://doi.org/10.1530/EDM-16-0148.
11. Ohyama K, Koike H, Iijima M, et al. IgG4-related neuropathy: a case report.
JAMA Neurol. 2013;70(4):502–5.
12. Baptista B, Casian A, Gunawardena H, D'Cruz D, Rice CM. Neurological
manifestations of IgG4-related disease. Curr Treat Options Neurol. 2017;
19(4):14.
13. Sugimoto T, Morita Y, Isshiki K, et al. Constrictive pericarditis as an emerging
manifestation of hyper-IgG4 disease. Int J Cardiol. 2008;130(3):e100–1.
14. Sakamoto A, Nagai R, Saito K, et al. Idiopathic retroperitoneal fibrosis,
inflammatory aortic aneurysm, and inflammatory pericarditis--retrospective
analysis of 11 case histories. J Cardiol. 2012;59(2):139–46.
15. Sekiguchi H, Horie R, Utz JP, Ryu JH. IgG4-related systemic disease
presenting with lung entrapment and constrictive pericarditis. Chest. 2012;
142(3):781–3.
16. Mori K, Yamada K, Konno T, et al. Pericardial involvement in IgG4-related
disease. Intern Med. 2015;54(10):1231–5.
17. Horie K, Tada N, Yamaguchi K, et al. Immunoglobulin G4-related constrictive
pericarditis identified by cytological examination of pericardial effusion: a
case report. J Med Case Reports. 2016;10(1):359.
18. Kabara M, Nakagawa N, Chinda J, et al. Diagnosis of IgG4-related systemic
disease by cytology of large pericardial effusion with fine needle aspiration.
Int J Cardiol. 2011;148(3):392–3.
19. Weiss MA, Aubry MC, Pflederer BR. A case of IgG4-related Aortitis and
pericarditis: diagnostic challenges and natural history. Am J Case Rep. 2018;
19:1232–6.
20. Patel NR, Anzalone ML, Buja LM, Elghetany MT. Sudden cardiac death due
to coronary artery involvement by IgG4-related disease: a rare, serious
complication of a rare disease. Arch Pathol Lab Med. 2014;138(6):833–6.
21. Gou SJ, Xue LJ, Hu ZX. Simultaneous occurrence of IgG4-related
Tubulointerstitial nephritis and colon adenocarcinoma with hepatic
metastasis: a case report and literature review. BMC Nephrol. 2019;20(1):23.
https://doi.org/10.1186/s12882-019-1205-5.
22. Della-Torre E, Lanzillotta M, Doglioni C. Immunology of IgG4-related disease.
Clin Exp Immunol. 2015;181(2):191–206.
23. Yamamoto M, Takahashi H, Shinomura Y. Mechanisms and assessment of
IgG4-related disease: lessons for the rheumatologist. Nat Rev Rheumatol.
2014;10(3):148–59.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Comai et al. BMC Nephrology          (2019) 20:418 Page 7 of 7
